Sana is Incorporating the Tested Immune Evasion Technology to Develop SC451, a HIP-modified, Stem Cell-Derived Therapy as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Normal ...

Sana's first-in-human study shows HIP technology allows islet cells to avoid immune rejection and produce insulin without immunosuppression. Reliance on initial results: The press release heavily ...

MAIA Biotechnology, Inc. ((MAIA)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

PDS Biotechnology is hosting a virtual key opinion leader event featuring notable experts in the field, which could enhance the company’s credibility and visibility in the oncological community. The ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

SAN FRANCISCO, March 23, 2026 (GLOBE NEWSWIRE)-- Siren Biotechnology today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application ...

On Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s ...

Scientists at Zhejiang University have engineered plants that glow on their own by inserting optimized fungal genes, producing second-generation specimens, reported to be more than 20 times brighter ...

You will have a wide range of opportunities for career preparation directly related to your field of study, all of which provide hands-on experiences that turn knowledge into know-how.

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...